Compare ACR & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACR | NYXH |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | Belgium |
| Employees | 4 | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.1M | 126.0M |
| IPO Year | N/A | 2021 |
| Metric | ACR | NYXH |
|---|---|---|
| Price | $18.59 | $1.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $24.50 | $9.33 |
| AVG Volume (30 Days) | 16.2K | ★ 35.7K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | $19.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.06 | $2.68 |
| 52 Week High | $24.61 | $8.59 |
| Indicator | ACR | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 33.26 | 19.11 |
| Support Level | $17.56 | N/A |
| Resistance Level | $19.64 | $5.02 |
| Average True Range (ATR) | 0.58 | 0.16 |
| MACD | -0.20 | -0.09 |
| Stochastic Oscillator | 4.58 | 4.35 |
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding, and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralized debt obligations, and private equity investments mainly issued by financial institutions.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.